NCT06928389View on ClinicalTrials.gov

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

536

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

June 30, 2030

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Ivonescimab, docetaxel

Patients will receive ivonescimab and docetaxel as an IV injection

DRUG

Placebo, docetaxel

Patients will receive placebo and docetaxel as an IV injection

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT06928389 - Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter